Search Within

Sarat Chandarlapaty

  1. "Body Imaging Service"
Formats
  1. Meeting Abstract (8)
  2. Journal Article (4)
Groups
  1. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (12)
  2. Body Imaging Service (12)
  3. Breast Medicine Service (12)
  4. Department of Medicine (12)
  5. GSK Faculty (12)
  6. Human Oncology and Pathogenesis Program (12)

More Groups

People
  1. Michael Berger (7)
  2. Clifford Hudis (6)
  3. David Solit (6)
  4. Larry Norton (6)
  5. Shanu Modi (6)
  6. Mary Ellen Moynahan (5)

More People

Years
  1. 2025 (1)
  2. 2024 (2)
  3. 2023 (1)
  4. 2022 (1)
  5. 2020 (1)
  6. 2017 (1)

More Years

Publications
  1. Journal of Clinical Oncology (4)
  2. Cancer Research (3)
  3. Annals of Oncology (2)
  4. Clinical Cancer Research (2)
  5. Nature Cancer (1)
Publishers
  1. American Association for Cancer Research (5)
  2. American Society of Clinical Oncology (4)
  3. Oxford University Press (2)
  4. Nature Research (1)

Results (12)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase II study of fulvestrant plus abemaciclib in hormone receptor–positive advanced or recurrent endometrial cancer
    Journal Article

    Green, A. K.; Zhou, Q.; Iasonos, A.; Zammarrelli, W. A. 3rd; Weigelt, B.; Ellenson, L. H.; Chhetri-Long, R.; Shah, P.; Loh, J.; Hom, V.; more...
    Clinical Cancer Research (2025)

    Fulltext@MSK | Save
  • Persistence and resistance of HER2 amplification after T-DM1 in a basket trial for patients with solid tumors
    Meeting Abstract

    Liu, D.; Arora, K.; Makker, V.; Buonocore, D.; Shen, R.; Yaeger, R.; Ginsberg, M. S.; Yeh, R.; Offin, M. D.; Solit, D.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • A phase II study of fulvestrant and abemaciclib in hormone receptor positive advanced or recurrent endometrial cancer
    Meeting Abstract

    Green, A.; Zhou, Q.; Iasonos, A.; Zammarrelli, W.; Weigelt, B.; Ellenson, L. H.; Chhetri-Long, R.; Shah, P.; Hom, V.; Erinjeri, J. P.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Final analysis of multi-histology basket trial expansion of ado-trastuzumab emtansine in patients with HER2 amplified cancers
    Meeting Abstract

    Liu, D.; Makker, V.; Buonocore, D. J.; Shen, R.; Yaeger, R.; Ginsberg, M. S.; Yeh, R.; Johnson, A.; Offin, M.; Solit, D. B.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Prediction of neoadjuvant treatment outcomes with multimodal data integration in breast cancer
    Meeting Abstract

    Khosravi, P.; Sutton, E. J.; Jee, J.; Dalfonso, T.; Fong, C. J.; Rose, D.; Da Silva, E. M.; Kohli, A.; Ho, D. J.; Ahmed, M. S.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors
    Journal Article

    Razavi, P.; Dickler, M. N.; Shah, P. D.; Toy, W.; Brown, D. N.; Won, H. H.; Li, B. T.; Shen, R.; Vasan, N.; Modi, S.; more...
    Nature Cancer (2020)

    Fulltext@MSK | Save
  • AKT inhibition in solid tumors with AKT1 mutations
    Journal Article

    Hyman, D. M.; Smyth, L. M.; Donoghue, M. T. A.; Westin, S. N.; Bedard, P. L.; Dean, E. J.; Bando, H.; El-Khoueiry, A. B.; Pérez-Fidalgo, J. A.; Mita, A.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Phase I study of PI3Kα inhibitor BYL719 + aromatase inhibitor (AI) in patients (pts) with hormone receptor-positive (HR+) metastatic breast cancer (MBC)
    Meeting Abstract

    Shah, P. D.; Moynahan, M. E.; Modi, S.; Hamilton, N.; Caravella, B. A.; Zamora, S.; Dang, C.; Gilewski, T.; Traina, T.; Comen, E.; more...
    Cancer Research (2015)

    Fulltext@MSK | Save
  • Phase I trial: PI3Kα inhibitor BYL719 plus aromatase inhibitor (AI) for patients with hormone receptor-positive (HR+) metastatic breast cancer (MBC)
    Meeting Abstract

    Shah, P. D.; Moynahan, M. E.; Modi, S.; Caravella, B. A.; Datko, F. M.; Zamora, S.; Comen, E.; Gilewski, T.; Sugarman, S. M.; D'Andrea, G.; more...
    Cancer Research (2015)

    Fulltext@MSK | Save
  • Phase I trial of daily PI3K alpha inhibitor BYL719 plus letrozole (L) or exemestane (E) for patients (pts) with hormone receptor-positive (HR plus ) metastatic breast cancer (MBC)
    Meeting Abstract

    Shah, P. D.; Modi, S.; Datko, F. M.; Moynahan, M. E.; Zamora, S.; D'Andrea, G.; Lake, D.; Goldfarb, S. B.; Patil, S.; Singh, S.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save